Clinical Observation of Paclitaxel or 5-Fluorouracil Combined with Nadaplatin in the Treatment of Ad-vanced Nasopharyngeal Carcinoma
10.6039/j.issn.1001-0408.2016.17.31
- VernacularTitle:紫杉醇与5-氟尿嘧啶分别联合奈达铂治疗晚期鼻咽癌的临床观察
- Author:
Guangsheng YANG
;
Lin CHEN
;
Yu LI
- Publication Type:Journal Article
- Keywords:
Advanced nasopharyngeal carcinoma;
Nedaplatin;
Paclitaxel;
5-fluorouracil
- From:
China Pharmacy
2016;27(17):2397-2399
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe clinical efficacy and safety of paclitaxel or 5-fluorouracil combined with nadaplatin in the treatment of advanced nasopharyngeal carcinoma(NPC). METHODS:42 patients with advanced NPC were randomly divided into observation group and control group(n=21). 2 groups of patients were treated with radiotherapy. Observation group received che-motherapy of paclitaxel(135 mg/m2,d1)and nedaplatin(80 mg/m2,d 2-4);control group received chemotherapy of 5-fluoroura-cil(500 mg/m2,d1-5)and nedaplatin(80 mg/m2,d1-3);a treatment course lasted for 3 weeks,and both groups received 2 courses of treatment. Clinical efficacy, survival rate and ADR were observed in 2 groups. RESULTS:The overall response rate was 95.2%in observation group and 90.5% in control group,with no significant difference between 2 groups (P>0.05). The 3-year overall survival rate and progression-free survival rate were 81.0% and 71.4% in observation group and 76.2% and 66.6% in control group,with no significant difference(P>0.05). The incidence of nausea and vomiting in observation group were lower than in con-trol group,while the incidence of oral mucosa inflammation was higher than control group,with statistical significance(P<0.05). CONCLUSIONS:The chemoradiotherapy of paclitaxel or 5-fluorouracil combined with nadaplatin have similar therapeutic efficacy for advanced NPC. ADR by chemoradiotherapy should be monitored closely and treated timely.
